{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:23:52Z","timestamp":1790796232849,"version":"4.1.0"},"reference-count":18,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,2,12]]},"published-print":{"date-parts":[[2019,3,29]]},"abstract":"<jats:p>Immunoglobulin A nephropathy (IgAN) is the most commonly diagnosed glomerulonephritis worldwide. It is usually idiopathic and may be associated with many other diseases. Recently, biological agents including tumour necrosis factor alpha (TNF\u03b1) inhibitors have been identified as a potential cause for IgAN. We report the case of a 39-year-old woman who presented with renal dysfunction and visible haematuria. She had a background of Crohn\u2019s disease (CD) and had been on adalimumab for 4\u2009years following a right hemicolectomy. Subsequently, she underwent a renal biopsy that demonstrated IgAN and adalimumab was ceased. Following a flare in her CD, she was commenced on infliximab, which led to remission of the IgAN and CD. This is the first case to demonstrate the occurrence of IgAN as a complication of a TNF\u03b1 inhibitor (adalimumab) that remained in remission despite the commencement of a second TNF\u03b1 inhibitor (infliximab).<\/jats:p>","DOI":"10.1136\/bcr-2018-226442","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T05:09:58Z","timestamp":1554181798000},"page":"e226442","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Adalimumab-induced IgA nephropathy"],"prefix":"10.1136","volume":"12","author":[{"given":"Aneesha Kaur","family":"Bhagat Singh","sequence":"first","affiliation":[{"name":"Internal Medicine, Royal Brisbane and Women\u2019s Hospital, Herston, Queensland, Australia"},{"name":"Faculty of Medicine, University of Queensland, Herston, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Sujeevan","family":"Jeyaruban","sequence":"additional","affiliation":[{"name":"Department of Medicine, Liverpool Hospital, NSW, Liverpool, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory John","family":"Wilson","sequence":"additional","affiliation":[{"name":"Renal, Royal Brisbane and Women\u2019s Hospital, Herston, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwarakanathan","family":"Ranganathan","sequence":"additional","affiliation":[{"name":"Renal, Royal Brisbane and Women\u2019s Hospital, Herston, Queensland, Australia"},{"name":"School of Medicine, Griffith University, Gold Coast, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,3,31]]},"reference":[{"key":"2025082709410038000_12.3.e226442.1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.50"},{"key":"2025082709410038000_12.3.e226442.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00834.x"},{"key":"2025082709410038000_12.3.e226442.3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/nep.12559","article-title":"Epidemiology of biopsy-proven glomerulonephritis in Queensland adults","volume":"21","author":"Jegatheesan","year":"2016","journal-title":"Nephrology"},{"key":"2025082709410038000_12.3.e226442.4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12882-016-0344-1","article-title":"The possible involvement of intestine-derived IgA1: a case of IgA nephropathy associated with Crohn\u2019s disease","volume":"17","author":"Terasaka","year":"2016","journal-title":"BMC Nephrol"},{"key":"2025082709410038000_12.3.e226442.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1206793"},{"key":"2025082709410038000_12.3.e226442.6","unstructured":"(GESA) GSoA. Australian Guideline for General practitioners and physicians inflammatory Bowel Disease (IBD). Melbourne: Digestive Health Foundation, 2013."},{"key":"2025082709410038000_12.3.e226442.7","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X08092548"},{"key":"2025082709410038000_12.3.e226442.8","first-page":"223","article-title":"IgA nephropathy onset in a Crohn\u2019s disease patient treated with Adalimumab","volume":"62","author":"Bruzzese","year":"2016","journal-title":"Minerva Gastroenterol Dietol"},{"key":"2025082709410038000_12.3.e226442.9","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1111\/ijd.12622","article-title":"Psoriasis-associated IgA nephropathy under infliximab therapy","volume":"54","author":"Kluger","year":"2015","journal-title":"Int J Dermatol"},{"key":"2025082709410038000_12.3.e226442.10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s12328-009-0112-x","article-title":"Infliximab treatment for crohn\u2019s disease in a patient with IgA nephropathy","volume":"2","author":"Ueno","year":"2009","journal-title":"Clin J Gastroenterol"},{"key":"2025082709410038000_12.3.e226442.11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-13-84"},{"key":"2025082709410038000_12.3.e226442.12","doi-asserted-by":"publisher","DOI":"10.3109\/08860221003710554"},{"key":"2025082709410038000_12.3.e226442.13","first-page":"812781","article-title":"Adalimumab (TNF \u03b1 Inhibitor) therapy exacerbates iga glomerulonephritis acute renal injury and induces lupus autoantibodies in a psoriasis patient","volume":"2013","author":"Wei","year":"2013","journal-title":"Case Rep Nephrol"},{"key":"2025082709410038000_12.3.e226442.14","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.3748\/wjg.v12.i30.4819","article-title":"Extraintestinal manifestations and complications in inflammatory bowel diseases","volume":"12","author":"Rothfuss","year":"2006","journal-title":"World J Gastroenterol"},{"key":"2025082709410038000_12.3.e226442.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-004-0696-z"},{"key":"2025082709410038000_12.3.e226442.16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.406"},{"key":"2025082709410038000_12.3.e226442.17","unstructured":"KDIGO. KDIGO clinical practice guidelines for Glomerulonephritis, 2012."},{"key":"2025082709410038000_12.3.e226442.18","first-page":"992","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"374","author":"Schena","year":"2016","journal-title":"N Engl J Med"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-226442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:41:11Z","timestamp":1756312871000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-226442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,29]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,31]]},"published-print":{"date-parts":[[2019,3,29]]}},"alternative-id":["10.1136\/bcr-2018-226442"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-226442","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,29]]}}}